AdventHealth adopts Paragonix Technologies’ cardiac system

17 March 2020 (Last Updated March 17th, 2020 11:37)

AdventHealth has adopted Paragonix Technologies’ SherpaPak Cardiac Transport System (CTS) for the static hypothermic preservation of donor hearts for transplantation.

AdventHealth adopts Paragonix Technologies’ cardiac system
Cardiac transplantation is considered the standard therapy for end-stage heart failure patients. Credit: Bryan Brandenburg.

AdventHealth has adopted Paragonix Technologies’ SherpaPak Cardiac Transport System (CTS) for the static hypothermic preservation of donor hearts for transplantation.

Paragonix SherpaPak CTS, the only commercially available FDA-cleared and CE-marked medical device, has been designed to safeguard hearts during the journey from donor to recipient patient.

The technology will enable the transport and preservation of a donor’s heart from around 1,000 miles away from AdventHealth’s transplant centre in Orlando, Florida, US.

AdventHealth Transplant Institute Thoracic Surgery director Dr Scott Silvestry said: “As a successful high volume advanced heart failure and heart transplant centre in Florida, our heart procurement teams are working around the clock to ensure our recipients on the waitlist receive a donor’s heart.

“We are thrilled about the addition of Paragonix SherpaPak Cardiac Transport System as a tool to provide best-in-class care of our transplant patients. Optimal preservation and quality management of the donor’s heart during transport from donor to recipient is paramount.”

The CTS enables physical and thermal protection of organs by using cold preservation techniques in a new suspension system.

Paragonix Technologies chairman and CEO Bill Edelman said: “Patients on the waitlist for a donor heart face so many medical uncertainties. The preservation of the donor’s heart they are waiting for should not be one of them.

“We are thrilled to contribute a key tool to the transplant teams in giving their transplant recipients every possible advantage on their journey of receiving a donor’s heart.”

Currently, Paragonix SherpaPak CTS is being evaluated by more than 20 major heart transplant centres in the US, adopted by 15 European transplant centres.